Effect of five novel 5-substituted tetrandrine derivatives on P-glycoprotein-mediated inhibition and transport in Caco-2 cells.

Tetrandrine (Tet) is a potent inhibitor that reverses P-glycoprotein-mediated multidrug resistance (MDR). A number of novel 5-substituted tetrandrine derivatives were synthesized by the authors. The present study aimed at identifying potential P-gp inhibitor candidates, and intracellular uptake and efflux experiments and Caco-2 cell-based Transwell transport studies were performed. It was demonstrated that all five test compounds were able to inhibit efflux and increase intracellular uptake of the P-gp substrate, rhodamine-123 (Rho-123); the test compounds were P-gp inhibitors. The transepithelial transport experiment indicated that the secretory (basolateral-to-apical) of Rho-123 decreased, the absorption (apical-to-basolateral) increased and the transport efflux ratio (ER) reduced in the presence of the five compounds. Among the compounds, fluobenzene-Tet (TF) exhibited similar inhibitory effect as Tet. Although the other four test compounds exhibited weaker inhibitory effects than Tet and TF, the compounds exhibited stronger inhibitory effects compared with the reference compound verapamil. The study demonstrated that the five novel 5-substituted tetrandrine derivatives are able to act as inhibitors of P-gp to overcome P-gp-mediated drug resistance.

[1]  M. Wink,et al.  Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from Stephania tetrandra can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells. , 2014, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[2]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[3]  Y. Shitara,et al.  Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells. , 2012, The American journal of tropical medicine and hygiene.

[4]  J. Iqbal,et al.  Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[5]  R. Mumper,et al.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. , 2010, Nanomedicine.

[6]  L. Lou,et al.  ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein , 2007, British Journal of Cancer.

[7]  A. Bernkop‐Schnürch,et al.  In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. , 2006, Biomaterials.

[8]  T. Fuchigami,et al.  Electrolytic partial fluorination of organic compounds. 83. Anodic fluorination of N-substituted pyrroles and its synthetic applications to gem-difluorinated heterocyclic compounds. , 2006, Journal of Organic Chemistry.

[9]  M. Reinisalo,et al.  Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  C. Choi,et al.  ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal , 2005, Cancer Cell International.

[11]  R. V. van Breemen,et al.  Caco-2 cell permeability assays to measure drug absorption , 2005, Expert opinion on drug metabolism & toxicology.

[12]  W. Fan,et al.  In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. , 2005, Anticancer research.

[13]  R. Borchardt,et al.  Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers. , 2004, Journal of pharmaceutical sciences.

[14]  Yu-Jen Chen Potential role of tetrandrine in cancer therapy. , 2002, Acta pharmacologica Sinica.

[15]  K. Luthman,et al.  Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. , 1999, The Journal of pharmacology and experimental therapeutics.

[16]  P Langguth,et al.  Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. , 1999, Journal of pharmaceutical sciences.

[17]  P. Artursson,et al.  Interplay Between CYP3A-Mediated Metabolism and Polarized Efflux of Terfenadine and Its Metabolites in Intestinal Epithelial Caco-2 (TC7) Cell Monolayers , 1999, Pharmaceutical Research.

[18]  Y Zhang,et al.  Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. , 1998, Journal of pharmaceutical sciences.

[19]  Shiyin Yee,et al.  In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth , 1997, Pharmaceutical Research.

[20]  W. Rubas,et al.  Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. , 1996, Journal of pharmaceutical sciences.

[21]  Y. Canitrot,et al.  [Use of rhodamine 123 for the detection of multidrug resistance]. , 1995, Bulletin du cancer.

[22]  H. Grunicke,et al.  Rapid functional assay for the detection of multidrug-resistant cells using the fluorescent dye rhodamine 123. , 1991, Blood.

[23]  P. Artursson,et al.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.

[24]  P. Artursson,et al.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.

[25]  Thomas J. Raub,et al.  Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. , 1989, Gastroenterology.

[26]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[27]  S. Ambudkar,et al.  Saracatinib (AZD0530) is a potent modulator of ABCB1‐mediated multidrug resistance in vitro and in vivo , 2013, International journal of cancer.

[28]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[29]  P. Twentyman,et al.  A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. , 1994, European journal of cancer.

[30]  P. Artursson Cell cultures as models for drug absorption across the intestinal mucosa. , 1991, Critical reviews in therapeutic drug carrier systems.